NPM1 Mutation clinical trials at UCSF

1 research study open to eligible people

An NPM1 mutation is a genetic change that can drive acute myeloid leukemia. UCSF is testing combinations of a new inhibitor drug with standard therapies in adults with relapsed or refractory disease. UCSF is measuring safety and antileukemic response in enrolled patients.

Showing trials for

  • Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    open to eligible people ages 18 years and up

    The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

    San Francisco, California and other locations

Last updated: